Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes

Shabnam Radbakhsh, George E. Barreto, Abigail R. Bland, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

Abstract

Amyloidosis is a concept that implicates disorders and complications that are due to abnormal protein accumulation in different cells and tissues. Protein aggregation-associated diseases are classified according to the type of aggregates and deposition sites, such as neurodegenerative disorders and type 2 diabetes mellitus. Polyphenolic phytochemicals such as curcumin and its derivatives have anti-amyloid effects both in vitro and in animal models; however, the underlying mechanisms are not understood. In this review, we summarized possible mechanisms by which curcumin could interfere with self-assembly processes and reduce amyloid aggregation in amyloidosis. Furthermore, we discuss clinical trials in which curcumin is used as a therapeutic agent for the treatment of diseases linking to protein aggregates.

Original languageEnglish
Pages (from-to)570-586
Number of pages17
JournalBioFactors
Volume47
Issue number4
DOIs
Publication statusPublished - 1 Jul 2021

Keywords

  • amyloid-beta (Aβ) plaque
  • amyloidosis
  • curcumin
  • islet amyloid polypeptide (IAPP)
  • α-Synuclein fibrillar

Fingerprint

Dive into the research topics of 'Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes'. Together they form a unique fingerprint.

Cite this